RU2012139319A - Химический способ - Google Patents

Химический способ Download PDF

Info

Publication number
RU2012139319A
RU2012139319A RU2012139319/04A RU2012139319A RU2012139319A RU 2012139319 A RU2012139319 A RU 2012139319A RU 2012139319/04 A RU2012139319/04 A RU 2012139319/04A RU 2012139319 A RU2012139319 A RU 2012139319A RU 2012139319 A RU2012139319 A RU 2012139319A
Authority
RU
Russia
Prior art keywords
formula
compound
ring
xiv
obtaining
Prior art date
Application number
RU2012139319/04A
Other languages
English (en)
Inventor
Юан Александер АРНОТТ
Джон КРОСБИ
Маттью Чарлз ЭВАНС
Джеймс Гейр ФОРД
Мартин Франсис ДЖОУНС
Кевин Уилльям ЛЕСЛИ
Айан Майкл МАКФАРЛЕЙН
Джордж Джозеф СИПЕНДА
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2012139319A publication Critical patent/RU2012139319A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1. Способ получения соединения формулы XI-1где А представляет собой подходящую кольцевую системуиз соединения формулы Х-1, где Lпредставляет собой уходящую группу;который включает (ж-2) взаимодействие соединения формулы Х-1 с соединением формулы VIIполучая соединение формулы XIV-1:(и-2) восстановление соединения формулы XIV-1, получая соединение формулы XI-1.2. Способ получения соединения формулы XI-1из соединения формулы Х-1, где Lпредставляет собой уходящую группу;который включает (ж-3) взаимодействие соединения формулы Х-1 с соединением формулы VIVI;получая соединение формулы XIV-2:(и-2) восстановление соединения формулы XIV-2, получая соединение формулы XI-2; и(к-3) гидролиз соединения формулы XI-2, получая соединение формулы XI-1.3. Способ по п.1 или 2, в котором кольцо А выбирают из хиназолина, хинолина, циннолина и пирролотриазина.4. Способ по п.3, в котором кольцо А представляет собой хиназолин и Lнаходится в 4-м положении хиназолинового кольца.5. Способ по п.3, в котором кольцо А представляет собой пирролотриазин и Lнаходится в 4-м положении пирролотриазинового кольца.6. Соединения формулы XIV, формулы XIV-1, формулы XIV-2 и формулы XI-2.

Claims (6)

1. Способ получения соединения формулы XI-1
Figure 00000001
где А представляет собой подходящую кольцевую систему
из соединения формулы Х-1, где L1 представляет собой уходящую группу;
Figure 00000002
который включает (ж-2) взаимодействие соединения формулы Х-1 с соединением формулы VII
Figure 00000003
получая соединение формулы XIV-1:
Figure 00000004
(и-2) восстановление соединения формулы XIV-1, получая соединение формулы XI-1.
2. Способ получения соединения формулы XI-1
Figure 00000005
из соединения формулы Х-1, где L1 представляет собой уходящую группу;
Figure 00000006
который включает (ж-3) взаимодействие соединения формулы Х-1 с соединением формулы VI
Figure 00000007
VI;
получая соединение формулы XIV-2:
Figure 00000008
(и-2) восстановление соединения формулы XIV-2, получая соединение формулы XI-2; и
Figure 00000009
(к-3) гидролиз соединения формулы XI-2, получая соединение формулы XI-1.
3. Способ по п.1 или 2, в котором кольцо А выбирают из хиназолина, хинолина, циннолина и пирролотриазина.
4. Способ по п.3, в котором кольцо А представляет собой хиназолин и L1 находится в 4-м положении хиназолинового кольца.
5. Способ по п.3, в котором кольцо А представляет собой пирролотриазин и L1 находится в 4-м положении пирролотриазинового кольца.
6. Соединения формулы XIV, формулы XIV-1, формулы XIV-2 и формулы XI-2.
RU2012139319/04A 2006-11-02 2012-09-14 Химический способ RU2012139319A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86403606P 2006-11-02 2006-11-02
US60/864,036 2006-11-02
US95740107P 2007-08-22 2007-08-22
US60/957,401 2007-08-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009120567A Division RU2481331C2 (ru) 2006-11-02 2007-11-01 Химический способ

Publications (1)

Publication Number Publication Date
RU2012139319A true RU2012139319A (ru) 2014-03-20

Family

ID=39284186

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012139318/04A RU2012139318A (ru) 2006-11-02 2012-09-14 Химический способ
RU2012139319/04A RU2012139319A (ru) 2006-11-02 2012-09-14 Химический способ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2012139318/04A RU2012139318A (ru) 2006-11-02 2012-09-14 Химический способ

Country Status (18)

Country Link
US (2) US7851623B2 (ru)
EP (3) EP2129657A2 (ru)
JP (1) JP2010508340A (ru)
KR (1) KR20090079247A (ru)
CN (3) CN102532108A (ru)
AR (1) AR063449A1 (ru)
AU (1) AU2007315982B2 (ru)
BR (1) BRPI0717751A2 (ru)
CA (1) CA2667920A1 (ru)
CL (1) CL2007003158A1 (ru)
IL (1) IL198117A0 (ru)
MX (1) MX2009004708A (ru)
MY (2) MY150219A (ru)
NO (1) NO20091588L (ru)
RU (2) RU2012139318A (ru)
SG (2) SG176446A1 (ru)
TW (1) TW200833667A (ru)
WO (1) WO2008053221A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
CN102603718B (zh) * 2012-02-08 2014-01-29 武汉凯斯瑞科技有限公司 西地尼布的合成方法
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN103275069B (zh) * 2013-05-22 2015-03-11 苏州明锐医药科技有限公司 西地尼布的制备方法
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN107840843A (zh) * 2017-10-17 2018-03-27 浙江工业大学义乌科学技术研究院有限公司 一种西地尼布中间体的合成方法
WO2023080193A1 (ja) * 2021-11-04 2023-05-11 日産化学株式会社 インドール化合物の製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100838617B1 (ko) * 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
MXPA03000874A (es) * 2000-08-09 2003-06-06 Astrazeneca Ab Compuestos quimicos.
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003291394B2 (en) * 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP4255057B2 (ja) 2003-03-12 2009-04-15 日本カーリット株式会社 導電性付与剤及び導電性材料
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
JP4676719B2 (ja) * 2004-06-04 2011-04-27 富山薬品工業株式会社 色素増感太陽電池用電解液及びそれを用いた色素増感型太陽電池
JP2006024785A (ja) 2004-07-08 2006-01-26 Tomiyama Pure Chemical Industries Ltd 電気二重層キャパシタ用非水電解液及び電気二重層キャパシタ
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
CN102584798A (zh) 2012-07-18
JP2010508340A (ja) 2010-03-18
CA2667920A1 (en) 2008-05-08
WO2008053221A3 (en) 2008-12-31
EP2540705A2 (en) 2013-01-02
BRPI0717751A2 (pt) 2013-10-22
SG176446A1 (en) 2011-12-29
AU2007315982A1 (en) 2008-05-08
US8754240B2 (en) 2014-06-17
US20110257395A1 (en) 2011-10-20
IL198117A0 (en) 2009-12-24
CL2007003158A1 (es) 2008-05-16
US20080221322A1 (en) 2008-09-11
KR20090079247A (ko) 2009-07-21
US7851623B2 (en) 2010-12-14
TW200833667A (en) 2008-08-16
WO2008053221A2 (en) 2008-05-08
CN102532108A (zh) 2012-07-04
MY179610A (en) 2020-11-11
CN101528688B (zh) 2012-09-05
AR063449A1 (es) 2009-01-28
MY150219A (en) 2013-12-31
EP2540706A3 (en) 2013-11-06
CN101528688A (zh) 2009-09-09
AU2007315982B2 (en) 2012-07-12
EP2540705A3 (en) 2013-10-30
MX2009004708A (es) 2009-05-15
RU2009120567A (ru) 2010-12-10
NO20091588L (no) 2009-05-28
RU2012139318A (ru) 2014-03-20
SG176447A1 (en) 2011-12-29
EP2540706A2 (en) 2013-01-02
EP2129657A2 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
RU2012139319A (ru) Химический способ
CA2407208A1 (en) Process for producing optically active sulfoxide derivative
CA2408914A1 (en) Novel triazolo pyrimidine compounds
RU2002135596A (ru) Новые триазолопиримидиновые соединения
RU2010102135A (ru) Способ получения пиразолов
BRPI0507422A (pt) processo para produção de ácido 2,5-dimetilfenilacético
JP2005509682A5 (ru)
RU2019105577A (ru) Способ получения соединения пиразоламида
CA2674764A1 (fr) Nouveau procede de synthese de l'agomelatine
RU2002123334A (ru) Производные дибензол (B, F) азепина и их получение
CN110330440A (zh) 一种以5-氯甲基糠醛制备5-氨基乙酰丙酸的工艺
AR055837A1 (es) Procedimientos para la preparacion de alc0holes aminoetoxibencilicos
CN1166626C (zh) 三或四取代苯基化合物、其制备方法及应用
WO2011062033A1 (ja) 芳香族ジフルオロ酢酸エステルの製造方法
EA200600308A1 (ru) Способ получения металлических солей среднецепочечных жирных кислот
CN107501148B (zh) 一种对称取代的磺酸酯化合物的制备方法
CN111454185B (zh) 一种可见光诱导芳胺化合物硫氰化的方法
RU2007140250A (ru) Способ получения сульфамат-карбоксилатных производных
ES2513091T3 (es) Procedimiento para producir un compuesto éster 1,2-cis-2-fluorociclopropano-1-carboxílico
RU2015111236A (ru) Способ получения производного оксазола
CY1111994T1 (el) Νεα μεθοδος για την παρασκευη σουλφονυλπυρρολιων ως αναστολεις hdac
RU2000126750A (ru) Способы получения промежуточных соединений
RU2675505C2 (ru) Способ получения n-алкил(фенил)-n,n-бис[4-алкокси(фенокси-, бензилокси-, проп-2-инилокси)-2-бутинил]аминов
CN87100382A (zh) 苯甲酰乙酸酯衍生物及其制备方法
ATE528358T1 (de) Verfahren zur herstellung einer azoverbindung